According to our new research study on "Anatomic Pathology Market Forecast to 2031 - Global Analysis - by Products and Services, Application, End User, and Geography," the market is anticipated to grow from US$ 30.22 billion in 2023 and is projected to reach US$ 53.27 billion by 2031; it is expected to register a CAGR of 7.3% during 2023-2031. The increase in the prevalence of cancer and kidney diseases and the rise in the number of strategic initiatives are contributing to the anatomic pathology market growth. However, the shortage of skilled professionals and stringent government regulations hamper the market growth. Further, the integration of artificial intelligence and machine learning is expected to bring new anatomic pathology market trends in the coming years.
Anatomical pathology is the study of organs and tissues to determine the causes and effects of particular diseases. Anatomic (or anatomical) pathology is the branch of medicine that studies the effect of disease on the structure of body organs, both as a whole (grossly) and microscopically. The primary role of anatomic pathology is to identify abnormalities that can help to diagnose disease and manage treatment. Although one of the frequent uses of anatomic pathology is to help identify and manage various types of tumors or cancers, it is also valuable in evaluating other conditions, including kidney and liver diseases, autoimmune disorders, and infections, for example.
North America accounted for a major share of the global anatomic pathology market in 2023. The North America anatomic pathology market is segmented into the US, Canada, and Mexico.
In the US, cancer has a significant impact on society. A few common cancer types in the country are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, and liver cancer. As per the National Cancer Institute, in 2021, ~17.43 individuals were living with cancer at any site in the US. The number of cancer survivors is projected to reach 22.2 million by 2030. This mounting prevalence of cancer cases is expected to increase the demand for pathologic diagnostic tests such as biopsies, fine-needle aspiration (FNA), genetic testing, and other novel techniques. Moreover, there has been unprecedented growth in innovative and improved medical technologies in the US in recent years.
This growth resulted in the development of advanced medical devices in the healthcare industry. Players operating in the US anatomic pathology market continuously focus on the development of innovative and convenient instruments and consumables for pathological procedures. In November 2023, Illumina Inc., US, a global leader in DNA sequencing and array-based technologies, introduced TruSight Oncology 500 ctDNA v2 (plate number 1 ctDNA v2), a new version of its distributed liquid biopsy assay that allows comprehensive noninvasive genomic profiling of circulating tumor DNA from blood, complementing tissue-based testing. In 2020, F. Hoffmann-La Roche received the US Food and Drug Administration (FDA) approval for the expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer. Thus, factors such as the high prevalence of cancer, strong presence of some major players, and availability of high-quality infrastructure for hospitals and clinical laboratories bolster the growth of the anatomic pathology market in the US.
Governments and private agricultural associations are highly focused on advancements in crop genomics to improve the characteristics of crops. The Agricultural Genome to Phenome Initiative (AG2PI) of the National Institute of Food and Agriculture focuses on collaborative engagements to develop a community of researchers studying both crop and animal genetics, which would lay the foundation for expanding knowledge about genomes and phenomes that are important to the agriculture sector in the US. The initiative is likely to result in the development of approaches to understanding how variable weather, environments, and production systems impact genetic diversity in crops and animals. Thus, the rising number of initiatives taken to foster studies related to the genetic makeup of crops for yield and quality improvement are likely to favor the anatomic pathology market in the US in the future.
Pathologists play an important role in developing and implementing molecular and genomic tests in practice. Personalized medicines are used in the treatment of diseases such as breast cancer and cardiovascular diseases. Personalized anticancer medicines exhibit fewer and less severe side effects than other types of treatment as they are designed for more specific action. Further, with the ongoing progress in research and clinical studies, personalized medicines are likely to reach even greater potential to improve the quality of patient care. Thus, the growing focus on personalized medicines is expected to boost the anatomic pathology market growth.
The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Organisation for Economic Co-operation and Development are among the primary and secondary sources referred to while preparing the anatomic pathology market report.
Anatomical pathology is the study of organs and tissues to determine the causes and effects of particular diseases. Anatomic (or anatomical) pathology is the branch of medicine that studies the effect of disease on the structure of body organs, both as a whole (grossly) and microscopically. The primary role of anatomic pathology is to identify abnormalities that can help to diagnose disease and manage treatment. Although one of the frequent uses of anatomic pathology is to help identify and manage various types of tumors or cancers, it is also valuable in evaluating other conditions, including kidney and liver diseases, autoimmune disorders, and infections, for example.
North America accounted for a major share of the global anatomic pathology market in 2023. The North America anatomic pathology market is segmented into the US, Canada, and Mexico.
In the US, cancer has a significant impact on society. A few common cancer types in the country are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, and liver cancer. As per the National Cancer Institute, in 2021, ~17.43 individuals were living with cancer at any site in the US. The number of cancer survivors is projected to reach 22.2 million by 2030. This mounting prevalence of cancer cases is expected to increase the demand for pathologic diagnostic tests such as biopsies, fine-needle aspiration (FNA), genetic testing, and other novel techniques. Moreover, there has been unprecedented growth in innovative and improved medical technologies in the US in recent years.
This growth resulted in the development of advanced medical devices in the healthcare industry. Players operating in the US anatomic pathology market continuously focus on the development of innovative and convenient instruments and consumables for pathological procedures. In November 2023, Illumina Inc., US, a global leader in DNA sequencing and array-based technologies, introduced TruSight Oncology 500 ctDNA v2 (plate number 1 ctDNA v2), a new version of its distributed liquid biopsy assay that allows comprehensive noninvasive genomic profiling of circulating tumor DNA from blood, complementing tissue-based testing. In 2020, F. Hoffmann-La Roche received the US Food and Drug Administration (FDA) approval for the expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer. Thus, factors such as the high prevalence of cancer, strong presence of some major players, and availability of high-quality infrastructure for hospitals and clinical laboratories bolster the growth of the anatomic pathology market in the US.
Governments and private agricultural associations are highly focused on advancements in crop genomics to improve the characteristics of crops. The Agricultural Genome to Phenome Initiative (AG2PI) of the National Institute of Food and Agriculture focuses on collaborative engagements to develop a community of researchers studying both crop and animal genetics, which would lay the foundation for expanding knowledge about genomes and phenomes that are important to the agriculture sector in the US. The initiative is likely to result in the development of approaches to understanding how variable weather, environments, and production systems impact genetic diversity in crops and animals. Thus, the rising number of initiatives taken to foster studies related to the genetic makeup of crops for yield and quality improvement are likely to favor the anatomic pathology market in the US in the future.
Growing Focus on Personalized Medicines to Provide Market Opportunities in Future
Personalized medicines are mainly designed by considering individuals' genetic profiles to guide the decisions made with respect to the prevention, diagnosis, and treatment of a disease. They provide an opportunity for drug manufacturers to develop agents that target patient groups that do not respond to medications as intended or for them who do not respond as expected to traditional healthcare practices. There is much evidence indicating that a substantial portion of the variability in drug response depends on factors that are genetically controlled, including age, nutrition, environmental exposure, and health status. Genomics plays an important role in the emergence of personalized medicines, as having the knowledge of a patient's genetic profile would help doctors in selecting an apt medication. Personalized medicines are helpful in improving healthcare by enabling each patient to receive earlier diagnoses, risk assessments, and optimal treatments.Pathologists play an important role in developing and implementing molecular and genomic tests in practice. Personalized medicines are used in the treatment of diseases such as breast cancer and cardiovascular diseases. Personalized anticancer medicines exhibit fewer and less severe side effects than other types of treatment as they are designed for more specific action. Further, with the ongoing progress in research and clinical studies, personalized medicines are likely to reach even greater potential to improve the quality of patient care. Thus, the growing focus on personalized medicines is expected to boost the anatomic pathology market growth.
Anatomic Pathology Market: Competitive Landscape and Key Developments
F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, BioGenex Laboratories Inc, Diapath S.p.A., Bio SB, Merck KGaA, BD, and PHC Holdings Corporation are among the key companies operating in the anatomic pathology market.The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Organisation for Economic Co-operation and Development are among the primary and secondary sources referred to while preparing the anatomic pathology market report.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the anatomic pathology market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the anatomic pathology market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the anatomic pathology market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Anatomic Pathology Market Landscape
5. Anatomic Pathology Market - Key Market Dynamics
6. Anatomic Pathology Market - Global Market Analysis
7. Anatomic Pathology Market Analysis - by Product and Services
8. Anatomic Pathology Market Analysis - by Application
9. Anatomic Pathology Market Analysis - by End User
10. Anatomic Pathology Market - Geographical Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Workflow Management System Market
- Appian Corp
- Bizagi
- Newgen Software Technologies Ltd.
- Nintex UK Ltd
- Oracle Corp
- Kissflow Inc
- Zapier Inc.
- S4BT Srl
- Analysis s.r.l.
- Bizzmine
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 178 |
| Published | August 2024 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value in 2023 | 30.22 Billion |
| Forecasted Market Value by 2031 | 53.27 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
